Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a4080c417b2f1de6

Jump to content

// Workers AI · dad joke modeDoes Biosplice Therapeutics have a cell-ebration?

From Wikipedia, the free encyclopedia
(Redirected from Samumed)
Biosplice Therapeutics
TypePrivately held company
IndustryRegenerative medicine
Founded2008; 18 years ago (2008) in San Diego, California, US
FounderOsman Kibar
FateRenamed from Samumed
Headquarters
San Diego, California, US
Websitewww.biosplice.com

Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.[1] It was founded in 2008 by Osman Kibar.[2]

Samumed's products in development target novel components of the Wnt signaling pathway.[3][4][5] The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced.[4][6]

References

[edit]
  1. ↑ "Small-molecule therapeutics using Biosplice Therapeutics". Business Outreach. 2023-08-16. Retrieved 2024-07-06.
  2. ↑ "Forbes Profile: Osman Kibar", "Forbes"
  3. ↑ Herper, Matthew."Cure Baldness? Heal Arthritis? Erase Wrinkles? An Unknown Billionaire's Quest To Reverse Aging", "Forbes", May 10, 2016
  4. 1 2 Ramsey, Lydia. "A $12 billion startup you've probably never heard wants to cure baldness and smooth out your wrinkles", "Business Insider", April 2, 2017
  5. ↑ Lee, Yoolim. "Eternal Youth Is the Next Big Bet for Singapore Venture Capitalist", "Bloomberg", February 9, 2017
  6. ↑ Jackson, Mandy. "ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III", "Informa Scrip", November 8, 2017"